EW
Edwards Lifesciences Corporation
Stock
$85.15−0.04 (−0.05%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5B | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B |
| Cost of revenue | $1.4B | $1.3B | $1.1B | $978M | $724M | $1.2B | $1.1B | $1.1B | $939M | $875M | $797M |
| Gross profit | $5.1B | $4.7B | $4.3B | $4.0B | $3.7B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B |
| R&D | $1.1B | $1.1B | $1.1B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M |
| SG&A | $2.2B | $2.1B | $1.8B | $1.6B | $1.4B | $1.5B | $1.2B | $1.2B | $1.1B | $991M | $905M |
| Other operating expenses | $329M | $305M | $101M | $177M | $41M | — | $419M | $92M | $325M | — | $68M |
| Operating income | $1.4B | $1.3B | $1.4B | $1.3B | $1.5B | $1.7B | $898M | $1.1B | $748M | $1.1B | $751M |
| Non-operating income | −$31M | $8.7M | $169M | $64M | $21M | $12M | $19M | $20M | $13M | −$55M | −$13M |
| Pretax income | $1.4B | $1.3B | $1.5B | $1.4B | $1.5B | $1.7B | $917M | $1.2B | $761M | $1.0B | $738M |
| Taxes | $413M | $199M | −$2.6B | −$30M | −$2.4M | $199M | $93M | $120M | $39M | $451M | $168M |
| Net income | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $584M | $570M |
| Diluted EPS | $1.74 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.90 | $0.87 |
| Diluted shares | — | 585.8M | 599.3M | 609.4M | 624.2M | 631.2M | 631.9M | 636.7M | 640.9M | 647.7M | 653.4M |
| Revenue growth | — | +11.5% | +8.6% | +12.2% | −14.7% | +19.3% | +0.9% | +16.8% | +8.4% | +15.9% | — |
| Gross margin | 77.8% | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% |
| Operating margin | 22.3% | 20.8% | 25.3% | 26.1% | 33.6% | 32.3% | 20.5% | 26.4% | 20.1% | 31.7% | 25.3% |
| Net margin | 15.4% | 17.7% | 76.7% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% | 17.0% | 19.2% |